Apyx Medical Corporation (APYX) Earnings Call Transcript & Summary

Good afternoon, ladies and gentlemen, and welcome to the Apyx Medical 2Q '26 Earnings Conference Call. [Operator Instructions ] This call is being recorded on Thursday, August 6, 2026. I would now like to turn the conference over to Jeremy Feffer, LifeSci Advisors. Please go ahead.

Thank you, and welcome, everyone, to our second quarter 2026 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer; and Matt Hill, Chief Financial Officer of Apyx. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements. That are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated. Including, without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website. I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please go ahead.

Thank you, Jeremy, and thank you all for joining us today. For our usual format on these quarterly calls, I will begin with a review of our performance over the past several months and then turn the call over to Matt for a review of our second quarter 2026 financial results, along with our guidance for full year 2026. We will then open the call for questions. Let me begin with a review of a few key highlights from our second quarter 2026 performance. We reported quarterly revenue of $13.9 million compared to $11.4 million in the same period last year, an increase of 22%. This growth was driven by a 28% increase in sales of our Surgical Aesthetics products to $12.4 million for the second quarter, primarily attributable to sales of our AYON Body Contouring System, increased Renuvion generator sales internationally and increased volume of single-use handpieces domestically. This marks our fourth consecutive quarter of AYON sales following its full commercial launch in September of 2025, and we are pleased to see increasing awareness of and demand for the platform across U.S. market. U.S. surgeons are increasingly recognizing the value of our integrated all-in-one body contouring platform, which combines the core technologies they rely on every single day into a single streamlined system. We believe the growing adoption reinforces AYON's differentiated value proposition. We recently took another important step in expanding AYON's capabilities during the quarter when we received expanded 510(k) clearance from the FDA to add power liposuction to the platform. Power liposuction uses a reciprocating cannula to support more efficient fat removal while reducing the physical effort required of the surgeon. Since receiving clearance, we conducted a limited commercial launch of the reusable power liposuction handpiece with key surgeons in targeted geographies. Based on positive feedback, we commenced initial commercial shipments in June of 2026. Overall, the sales and interest that we are seeing in AYON comes at an important time for the body contouring market. As we have discussed on prior calls, the continued rapid adoption of GLP-1 medications is reshaping the patient population and creating what we believe will be a meaningful long-term opportunity for our business. While these therapies are helping a growing number of patients achieve significant weight loss, many are left with loose or lax skin that cannot be adequately addressed through nonsurgical treatments. Once these patients reach or approach their target weight, we believe many will seek procedures to address skin laxity, excess fat and overall body contouring in a more comprehensive manner. AYON seamlessly combines advanced fat removal technologies, Renuvion's tissue contraction and electrosurgical capabilities and empower surgeons to deliver the most comprehensive body contouring treatments for patients while positioning Apyx to address this growing market. We believe in science-based medicine and our clinical strategy is an important part of establishing that value proposition. During the quarter, a retrospective study of 113 patients showed that a combination procedure using Renuvion and liposuction was associated with statistically significantly higher patient satisfaction, lower rates of abdominoplasty and surgical revision and a comparable complication rate versus procedures that use liposuction alone. These findings are important because they suggest that Renuvion may help surgeons deliver a more satisfying aesthetic outcome while potentially reducing the need for more invasive or follow-on procedures without increasing the observed complication rate. We also reported data from prospective study evaluating a single session treatment combining Avéli and Renuvion. The study demonstrated visible improvements in cellulite and skin laxity, including measurable reductions in dimple volume, surface area and depth. In a subset of patients, histological analysis also showed increases in collagen and elastin through 180 days, providing evidence of progressive tissue remodeling following treatment. Together, these peer-reviewed publications add to the clinical foundation supporting Renuvion and demonstrate its potential value across a broader range of aesthetic body contouring procedures. In addition, the publications reinforce the important point that as patients' needs become more complex, surgeons increasingly require technologies that can address not only fat removal, but also skin quality, laxity and structural factors that influence the final aesthetic result. We also took the opportunity this quarter to build broader awareness of our platform, showcasing Renuvion and AYON at Miami Swim Week through our Body by Apex showcase. The event featured real Renuvion patients sharing their treatment journeys and walking the runway, allowing us to highlight the aesthetic outcomes and the self-confidence those patients gain from their procedures. This year's event underscored the progress we have made since last summer. At that time, AYON was still in the early stages of its commercial journey. This year, we returned with a commercially available platform supported by growing physician engagement, real-world experience and enhanced capabilities through the FDA clearance of power liposuction, which has resulted in AYON gaining traction across the market. Together, those milestones reflect the disciplined execution of our commercial strategy and reinforce the foundation of the opportunity ahead. These accomplishments demonstrate the progress we are making in executing our commercial strategy and reinforce our confidence in the long-term opportunity for our cohesive platform of AYON and Renuvion. Before I wrap up, I would like to briefly touch on our recent announcement that Stavros Vizirgianakis has been appointed Executive Chairman of our Board of Directors. Over the past 2 years, Stavros has become an increasingly important partner to both our Board and management team. He has been deeply engaged in helping shape our strategic priorities, supporting key financing initiatives and strengthening our operational focus and providing valuable guidance as we execute our commercial strategy. Formalizing his role as Executive Chairman recognizes the level of involvement he already has within the company and reflects our shared commitment to creating long-term shareholder value. Stavros brings decades of leadership experience and extensive industry network and a proven track record of building and growing health care businesses. I look forward to continuing to work closely with him as we execute on the significant opportunities ahead for Apyx. I will now turn the call over to Matt for a review of our second quarter 2026 financial results in more detail, along with our financial guidance for 2026.

Thank you, Charlie. Before I get started, please note that all references to our second quarter financial results will be on a GAAP and year-over-year basis, unless noted otherwise. As Charlie mentioned, total revenue for the second quarter of '26 increased 22% to $13.9 million compared to $11.4 million in the prior year period. Revenue for the Surgical Aesthetics segment increased 28% or $2.7 million to $12.4 million compared to $9.7 million for the prior year period. This growth was driven by sales of AYON, increased sales of generators internationally and increased volume of single-use handpieces domestically. Turning to the OEM segment. Sales decreased 12% or approximately $0.2 million to $1.5 million for the second quarter of '26 compared to $1.7 million for the second quarter of '25. The decrease in OEM sales was due to a decrease in sales volume to existing customers. With the increased focus on surgical aesthetics, we continue to expect our OEM segment revenue will decrease for the year, and this trend will continue over time. Domestic revenue increased 21% year-over-year to $9.4 million and international revenue increased 24% year-over-year to $4.5 million for the second quarter of '26. Gross profit for the second quarter '26 increased 25% to $8.9 million compared with $7.1 million in the prior year period. Gross profit margin for the second quarter of '26 increased to 63.9% compared to 62.3% in the prior year period. The increase in gross margin was primarily attributable to mix between our segments with Surgical Aesthetics comprising a higher percentage of total sales and product mix within our OEM segment. This was partially offset by tariffs that began affecting us in the second half of 2025. Operating expenses increased to $10.7 million for the second quarter of '26 compared to $9.7 million for the prior year period. The increase was driven by $1.0 million increase in selling, general and administrative expenses and $0.3 million increase in salaries and related costs, partially offset by a $0.3 million decrease in professional services. Loss from operations was $1.8 million compared with a loss from operations of $2.6 million for the second quarter of '25. Net loss attributable to stockholders was $3.2 million or $0.07 per share for the second quarter of '26 compared with $3.8 million or $0.09 per share in the prior year period. Adjusted EBITDA loss was $0.7 million for the second quarter of '26 compared to an adjusted EBITDA loss of $2.0 million in the second quarter of '25. As a reminder, we provide a detailed reconciliation from the net loss attributable to stockholders to non-GAAP adjusted EBITDA in our earnings press release. For the 3 months ended June 30, 2026, net cash used in operating activities was $3.5 million compared to $1.2 million used in the prior year period. The increase was primarily due to changes in working capital, partially offset by a reduction in operating loss. As of June 30, 2026, the company had cash and cash equivalents of $27.6 million. We believe, based on our projections, including uptake of the AYON platform, working capital management and our strict cost controls, we expect to maintain sufficient liquidity into 2028. We are focused on growing sales, managing expenses and getting to cash flow positive as quickly as possible. Turning to our 2026 guidance. We are reaffirming our full year total revenue guidance in the range of $59.0 million to $60.0 million compared with $52.8 million reported for the year ended December 31, 2025. Our guidance continues to assume Surgical Aesthetics segment revenue in the range of $54.0 million to $55.0 million compared with approximately $45.3 million for 2025, and OEM revenue of approximately $5.0 million compared with approximately $7.5 million for 2025. In addition, we continue to expect gross margins in the range of 62% to 63% and total operating expenses not to exceed $45.0 million for the full year. This completes our prepared remarks. Charlie and I will now open the call for questions. Operator?

[Operator Instructions] We will now take our first question, and this comes from Dave Turkaly from Citizens.

Charlie, I got -- I think I have a bunch of questions. I want to ask that you may not want to answer, but let me just start off by asking you in terms of the users that you're hitting with the new AYON product, are there non-Renuvion folks? And any people sort of like outside of your core plastic docs?

Yes. So the answer to the first part of the question is yes. We are getting people that have never used Renuvion before that are buying the AYON platform. So that is the first part of your question. And the second part of your question is, for the most part, it's all plastic or cosmetics that are doing, obviously, bodies and seeing these GLP-1 patients coming into their practice. Those are the people who are acquiring AYON right now.

Great. I think we all understand like the footprint difference of having kind of an all-in-one option, but it seems like there's some other benefits. You mentioned Power Lipo, but even with your ultra Lipo and some of the other features that could save the physician's time. So I was wondering if you could just maybe walk us through that quickly.

Yes. It's a good question because what you see from the outside is just the fact that everything is put together in a nice streamlined package, but that really is the least important part of the story. The most important part of the story is that every technology that is in AYON is better than the existing technologies that exist today. And remember, the liposuction that we have for the ultrasonic liposuction, that has been out since we originally launched AYON, but we just got approval for the power-assisted piece in May of this last year. And the power-assisted piece is a very important part of AYON because that is the part that defines and sculpts the body and actually removes the fat or puts the fat back into other areas, and that is the part that takes the longest in the procedure. So the ultrasonic separates the fat and then the Power Assist comes in and takes the fat out. And then through our closed-loop contouring, you can put it back in. But let's not forget that in the quarter, we just did a soft launch in the quarter, and we got feedback from the physicians. That feedback was incredibly well received on the Power Lipo product. In fact, it was exceptional. And then we only started to ship to a very few units in June, okay? So we still have work to do as far as building Power Lipo handpieces and getting them out to customers that are still waiting for them.

And the next question comes from Alex Fuhrman from Lucid Capital Markets.

Congratulations on another strong quarter of double-digit growth. I wanted to ask about gross margin. It was up very nicely year-over-year in the first and second quarter this year. It looks like the guidance implies that it's going to come in a little bit sequentially. Can you talk a little bit about what's driving that? It seems like the mix shift to surgical aesthetics has certainly been helping things, and that's expected to continue. So any color on what's driving that change in gross margin would be helpful.

Yes. Look, I don't know that it is too much of a change. There's always a mix in there between international and OUS and U.S. And so I don't know that fundamentally that there's any change. It has overperformed the first 2 quarters, which is obviously very nice. We're very happy with that. But remember, we're in the process of rolling out the Power Lipo right now. And obviously, the first ones of anything that you make are going to be the most expensive ones, and you're going to see that get better and better as time goes on as manufacturing has more throughput as we get better at making them and all of those things. And so when we're looking at the second half, remember, we're just gearing up on the Power Lipo handpiece. And so there's -- we're looking at that and making sure that we're able to deliver and do the things that we need to do there.

The next question comes from Matthew Hewitt from Craig-Hallum.

This is Tollef Kohrman on for Matt Hewitt. So for Power Lipo, is that at all embedded into the guidance?